8pjc
From Proteopedia
(Difference between revisions)
| (2 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Crystal structure of human insulin desB30 precursor with an Alanine-Alanine-Lysine C-peptide in dimer (T2) conformation== | |
| + | <StructureSection load='8pjc' size='340' side='right'caption='[[8pjc]], [[Resolution|resolution]] 2.14Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[8pjc]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8PJC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8PJC FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.14Å</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8pjc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8pjc OCA], [https://pdbe.org/8pjc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8pjc RCSB], [https://www.ebi.ac.uk/pdbsum/8pjc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8pjc ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Since the first administration of insulin to a person with diabetes in 1922, scientific contributions from academia and industry have improved insulin therapy and access. The pharmaceutical need for insulin is now more than 40 tons annually, half of which is produced by recombinant secretory expression in Saccharomyces cerevisiae. We discuss how, in this yeast species, adaptation of insulin precursors by removable structural elements is pivotal for efficient secretory expression. The technologies reviewed have been implemented at industrial scale and are seminal for the supply of human insulin and insulin analogues to people with diabetes now and in the future. Engineering of a target protein with removable structural elements may provide a general approach to yield optimisation. | ||
| - | + | Molecular engineering of insulin for recombinant expression in yeast.,Kjeldsen T, Andersen AS, Hubalek F, Johansson E, Kreiner FF, Schluckebier G, Kurtzhals P Trends Biotechnol. 2024 Apr;42(4):464-478. doi: 10.1016/j.tibtech.2023.09.012. , Epub 2023 Oct 24. PMID:37880066<ref>PMID:37880066</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| - | [[Category: Johansson | + | <div class="pdbe-citations 8pjc" style="background-color:#fffaf0;"></div> |
| - | [[Category: Schluckebier | + | == References == |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Homo sapiens]] | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Johansson E]] | ||
| + | [[Category: Schluckebier G]] | ||
Current revision
Crystal structure of human insulin desB30 precursor with an Alanine-Alanine-Lysine C-peptide in dimer (T2) conformation
| |||||||||||
